ACAD
27.55
-0.46
-1.64%
AEMD
2.05
-0.01
-0.49%
APRI
1.01
-0.03
-2.88%
ARNA
1.36
+0.02
+1.49%
ATEC
2
-0.09
-4.31%
CNAT
5.3
0.00
0.00%
CRXM
0.17
+0.05
+40.50%
CYTX
1.08
+0.12
+12.50%
DXCM
67.58
-1.27
-1.84%
GNMK
13.09
-0.12
-0.91%
HALO
12.74
-0.05
-0.39%
ILMN
174.72
-0.2
-0.11%
INNV
0.107
-0.001
-0.7442%
INO
7.12
+0.03
+0.42%
ISCO
1.5
-0.14
-8.54%
ISIS
57.56
0.00
0.00%
LGND
113.74
+0.3
+0.26%
LPTN
2.93
0.00
0.00%
MBVX
1.67
-0.04
-2.34%
MEIP
1.65
+0.01
+0.61%
MNOV
5.76
+0.11
+1.95%
MRTX
3.4
-0.25
-6.85%
MSTX
0.131
0.00
0.00%
NBIX
53.53
-0.11
-0.21%
NUVA
71.92
+0.38
+0.53%
ONCS
0.92
+0.02
+2.22%
ONVO
2.83
+0.02
+0.71%
OREX
2.95
-0.08
-2.64%
OTIC
13.4
+0.15
+1.13%
QDEL
24.61
+0.04
+0.16%
RCPT
231.96
0.00
0.00%
RGLS
1.425
+0.05
+3.636%
RMD
69.584
+0.074
+0.1063%
SCIE
0.001
+0.00
+20.0000%
SPHS
2.42
-0.06
-2.42%
SRNE
1.575
-0.15
-8.696%
TROV
0.736
-0.04
-5.1804%
VICL
2.3
+0.01
+0.44%
VOLC
18
0.00
0.00%
ZGNX
12.75
-0.35
-2.67%
ACAD
27.55
-0.46
-1.64%
AEMD
2.05
-0.01
-0.49%
APRI
1.01
-0.03
-2.88%
ARNA
1.36
+0.02
+1.49%
ATEC
2
-0.09
-4.31%
CNAT
5.3
0.00
0.00%
CRXM
0.17
+0.05
+40.50%
CYTX
1.08
+0.12
+12.50%
DXCM
67.58
-1.27
-1.84%
GNMK
13.09
-0.12
-0.91%
HALO
12.74
-0.05
-0.39%
ILMN
174.72
-0.2
-0.11%
INNV
0.107
-0.001
-0.7442%
INO
7.12
+0.03
+0.42%
ISCO
1.5
-0.14
-8.54%
ISIS
57.56
0.00
0.00%
LGND
113.74
+0.3
+0.26%
LPTN
2.93
0.00
0.00%
MBVX
1.67
-0.04
-2.34%
MEIP
1.65
+0.01
+0.61%
MNOV
5.76
+0.11
+1.95%
MRTX
3.4
-0.25
-6.85%
MSTX
0.131
0.00
0.00%
NBIX
53.53
-0.11
-0.21%
NUVA
71.92
+0.38
+0.53%
ONCS
0.92
+0.02
+2.22%
ONVO
2.83
+0.02
+0.71%
OREX
2.95
-0.08
-2.64%
OTIC
13.4
+0.15
+1.13%
QDEL
24.61
+0.04
+0.16%
RCPT
231.96
0.00
0.00%
RGLS
1.425
+0.05
+3.636%
RMD
69.584
+0.074
+0.1063%
SCIE
0.001
+0.00
+20.0000%
SPHS
2.42
-0.06
-2.42%
SRNE
1.575
-0.15
-8.696%
TROV
0.736
-0.04
-5.1804%
VICL
2.3
+0.01
+0.44%
VOLC
18
0.00
0.00%
ZGNX
12.75
-0.35
-2.67%
Home » Archive by Category

Xconomy

Drug-Hunting Startup From Scripps Attracts Celgene Alum, $50M Backing

February 2, 2017 – 12:09 pm

A team of decorated academic chemists in San Diego have been working since 2014 on a biotech startup that aims to find new drugs faster. The company now has a lot of cash in the bank and a well-known…

[[Click headline to continue reading.]]

Insurer UHC Will Cover Biogen Spine Drug, But With Limits And Proof

February 2, 2017 – 7:25 am

[Updated, 1:57 pm E.T., see below] Another major U.S. health insurer, UnitedHealthCare, has said it would cover the first-ever approved drug for the rare disease spinal muscular atrophy, a closely…

[[Click headline to continue reading.]]

Seed-Stage Deals Show Growing Diversity of Agtech Investments

February 1, 2017 – 11:59 am

Fundraising is tough for startups but it’s particularly difficult in agriculture, a sector that has fewer firms focused on agtech investments. The dynamics are starting to change, though. A growing…

[[Click headline to continue reading.]]

Still No Official Word From Biopharma Groups About Trump Travel Ban

January 31, 2017 – 4:09 am

Four days after President Donald Trump issued an order to temporarily ban U.S. entry for people from seven Muslim-majority countries—and for all refugees—the drug industry’s two…

[[Click headline to continue reading.]]

Bio Roundup: Trump News, Anthem’s Stand, Diversity by 2056 & More

January 27, 2017 – 5:55 am

It was a wild week in biotech and on Capitol Hill. A new study showed it may take another 40 years to achieve gender parity in public biotech boardrooms. Tensions continued to mount between…

[[Click headline to continue reading.]]

Jounce Gets $102M As Biotech IPOs Gain Steam in ’17

January 27, 2017 – 3:44 am

Jounce Therapeutics has gone ahead of its projections and raised roughly $102 million in an IPO, continuing an early, yet successful trend for biotechs trying to go public in 2017. The Cambridge, MA,…

[[Click headline to continue reading.]]

AnaptysBio Adds More Shares, Raises $75M in Stock Market Debut

January 26, 2017 – 9:59 am

AnaptysBio is the first U.S. biotech company to go public this year, raising $75 million in an IPO intended to finance development of antibody-based drugs for inflammatory disorders. The San…

[[Click headline to continue reading.]]

Just Four Months After Series A, Delinia Sells to Celgene For $300M

January 26, 2017 – 5:35 am

It didn’t take long for startup Delinia to entice a big drug developer: Just over four months after emerging from stealth and raising a Series A round, the company, developing drugs for a range of…

[[Click headline to continue reading.]]

Inspired by NFL Teammate, Aethlon Seeks Diagnostic for Brain Injuries

January 25, 2017 – 6:56 am

Just as the NFL marketing machine is stoking the build-up to Super Bowl LI, a San Diego diagnostic company headed by a former Denver Broncos player has unveiled plans for a new clinical study of…

[[Click headline to continue reading.]]

Anthem Caps Coverage Of Biogen Spine Drug Despite Wide FDA Approval

January 24, 2017 – 10:50 am

One of the nation’s major health insurers has placed limitations on access to the first-ever approved drug for the rare spinal muscular atrophy, validating patient fears that the high price tag of…

[[Click headline to continue reading.]]